<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210001</url>
  </required_header>
  <id_info>
    <org_study_id>1245.19</org_study_id>
    <secondary_id>2009-016154-40</secondary_id>
    <nct_id>NCT01210001</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Background Therapy of Pioglitazone Alone or in Combination With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients
      in order to provide these data for approval for BI 10773 by regulatory authorities as an
      antidiabetic agent as add-on therapy to pioglitazone alone or in combination with metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change From Baseline in HbA1c after 24 weeks.
Note that adjusted means are provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c Change From Baseline for Pio and Met Background Medication Patients</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change From Baseline in HbA1c after 24 weeks for patients with pioglitazone (pio) and metformin (met) background medication only.
Note that adjusted means are provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment.
Note that adjusted means are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in body weight after 24 weeks.
Note that adjusted means are provided.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hypoglycaemic Events</measure>
    <time_frame>From first drug administration until 7 days after last intake of study drug, up to 256 days</time_frame>
    <description>Number of patients with hypoglycaemic events, as reported as adverse events.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">499</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BI 10773</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching BI 10773 low dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching BI 10773 high dose</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching BI 10773 high dose</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching BI 10773 high dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus prior to informed consent.

          2. Male and female patients on diet and exercise regimen who are pre-treated with
             pioglitazone alone or in combination with metformin. The treatment regimen should be
             unchanged for 12 weeks prior to randomisation.

          3. HbA1c of &gt;/= 7.0% and &lt;/= 10.0% at Visit 1 (screening).

          4. Age &gt;/= 18.

          5. BMI &lt;/= 45 kg/m2 (Body Mass Index) at Visit 1 (screening).

          6. Signed and dated written informed consent by date of Visit 1 in accordance with Good
             Clinical Practice (GCP) and local legislation.

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia with a glucose level &gt; 240 mg/dl (&gt; 13.3 mmol/l) after an
             overnight fast during placebo run-in and confirmed by a second measurement (not on the
             same day).

          2. Any other antidiabetic medication within 12 weeks prior to randomisation, except those
             defined as the permitted background therapy via inclusion criteria no. 2.

          3. Myocardial infarction, stroke or transient ischaemic attack (TIA) within 3 months
             prior to informed consent.

          4. Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT/SGPT), aspartate transaminase (AST/SGOT), or alkaline phosphatase above 3 x upper
             limit of normal (ULN) as determined during screening or during the placebo run-in
             period (i.e. at a visit prior to the randomisation visit, Visit 3).

          5. Impaired renal function, defined as eGFR (estimated Glomerular Filtration Rate) &lt; 30
             ml/min (severe renal impairment, MDRD [Modification of Diet in Renal Disease] formula)
             as determined during screening or during the placebo run-in period (i.e. at a visit
             prior to the randomisation visit, Visit 3).

          6. Bariatric surgery within the past two years and other gastrointestinal surgeries that
             induce chronic malabsorption.

          7. Medical history of cancer (except for basal cell carcinoma) and/or treatment for
             cancer within the last 5 years .

          8. Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells (e.g.
             malaria, babesiosis, haemolytic anaemia).

          9. Contraindications to pioglitazone according to the local label.

         10. Contraindication to pioglitazone and/or metformin (relevant only for those patients
             who enter the study with both these background therapies) according to the local
             labels.

         11. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to
             informed consent or any other treatment at the time of screening (i.e. surgery,
             aggressive diet regimen etc.) leading to unstable body weight.

         12. Current treatment with systemic steroids at time of informed consent or change in
             dosage of thyroid hormones within 6 weeks prior to informed consent or any other
             uncontrolled endocrine disorder except T2D.

         13. Pre-menopausal women (last menstruation &lt;/= 1 year prior to informed consent) who:

               -  are nursing or pregnant or

               -  are of child bearing potential and are not practicing an acceptable method of
                  birth control, or do not plan to continue using this method throughout the trial
                  and do not agree to submit to periodic pregnancy testing during participation in
                  the trial. Acceptable methods of birth control include tubal ligation,
                  transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable
                  or injectable contraceptives, sexual abstinence (if acceptable to local
                  authorities), double barrier method and vasectomised partner.

         14. Alcohol or drug abuse within the 3 months prior to informed consent that would
             interfere with trial participation or any ongoing condition leading to a decreased
             compliance to study procedures or study drug intake.

         15. Participation in another trial with an investigational drug within 30 days prior to
             informed consent.

         16. Any other clinical condition that would jeopardise patient safety while participating
             in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.19.10056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10162 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10161 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10149 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10163 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10141 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10160 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essex</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20012 G.A. Research Associates Ltd.</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Erie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.20041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nikaia</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gulbarga</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kartanaka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai, Maharastra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Patna</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.91016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu City, N/A, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Davao City, N/A, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasig City, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan City, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.66003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saimai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.66004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Udon Thani, Thailand</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.75002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.75001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.75005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.75006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.75004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.19.75003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Greece</country>
    <country>India</country>
    <country>Philippines</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refusal to continue,not due toAE</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): all patients treated with at least one dose of randomised study medication</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="165"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="168"/>
            <count group_id="B4" value="498"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="10.5"/>
                    <measurement group_id="B2" value="54.7" spread="9.9"/>
                    <measurement group_id="B3" value="54.2" spread="8.9"/>
                    <measurement group_id="B4" value="54.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline</title>
        <description>Change From Baseline in HbA1c after 24 weeks.
Note that adjusted means are provided.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline</title>
          <description>Change From Baseline in HbA1c after 24 weeks.
Note that adjusted means are provided.</description>
          <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.07"/>
                    <measurement group_id="O2" value="-0.59" spread="0.07"/>
                    <measurement group_id="O3" value="-0.72" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing to adjust for multiple comparisons within each dose level, alpha split equally between the doses (2.5%). Empa versus placebo change from baseline in HbA1c was the first step in each hierarchical sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, background antidiabetic medication, renal function at baseline and baseline HbA1c.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing to adjust for multiple comparisons within each dose level, alpha split equally between the doses (2.5%). Empa versus placebo change from baseline in HbA1c was the first step in each hierarchical sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, background antidiabetic medication, renal function at baseline and baseline HbA1c.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline</title>
        <description>Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment.
Note that adjusted means are provided.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline</title>
          <description>Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment.
Note that adjusted means are provided.</description>
          <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" spread="2.61"/>
                    <measurement group_id="O2" value="-17.00" spread="2.63"/>
                    <measurement group_id="O3" value="-21.99" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing to adjust for multiple comparisons within each dose level, alpha split equally between the doses (2.5%). Empa versus placebo change from baseline in FPG was the second step in each hierarchical sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, background antidiabetic medication, renal function at baseline, baseline HbA1c and baseline FPG</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-23.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.71</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.81</ci_lower_limit>
            <ci_upper_limit>-15.15</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing to adjust for multiple comparisons within each dose level, alpha split equally between the doses (2.5%). Empa versus placebo change from baseline in FPG was the second step in each hierarchical sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, background antidiabetic medication, renal function at baseline, baseline HbA1c and baseline FPG</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-28.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.68</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.73</ci_lower_limit>
            <ci_upper_limit>-20.19</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change From Baseline</title>
        <description>Change from baseline in body weight after 24 weeks.
Note that adjusted means are provided.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Change From Baseline</title>
          <description>Change from baseline in body weight after 24 weeks.
Note that adjusted means are provided.</description>
          <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.21"/>
                    <measurement group_id="O2" value="-1.62" spread="0.21"/>
                    <measurement group_id="O3" value="-1.47" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing to adjust for multiple comparisons within each dose level, alpha split equally between the doses (2.5%). Empa versus placebo change from baseline in body weight was the third step in each hierarchical sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, background antidiabetic medication, renal function at baseline, baseline HbA1c and baseline weight</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.64</ci_lower_limit>
            <ci_upper_limit>-1.27</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing to adjust for multiple comparisons within each dose level, alpha split equally between the doses (2.5%). Empa versus placebo change from baseline in body weight was the third step in each hierarchical sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, background antidiabetic medication, renal function at baseline, baseline HbA1c and baseline weight</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.49</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline for Pio and Met Background Medication Patients</title>
        <description>Change From Baseline in HbA1c after 24 weeks for patients with pioglitazone (pio) and metformin (met) background medication only.
Note that adjusted means are provided.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value for patients on pioglitazone and metformin background medication. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline for Pio and Met Background Medication Patients</title>
          <description>Change From Baseline in HbA1c after 24 weeks for patients with pioglitazone (pio) and metformin (met) background medication only.
Note that adjusted means are provided.</description>
          <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value for patients on pioglitazone and metformin background medication. Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.08"/>
                    <measurement group_id="O2" value="-0.55" spread="0.08"/>
                    <measurement group_id="O3" value="-0.70" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing to adjust for multiple comparisons within each dose level, alpha split equally between the doses (2.5%). Empa vs placebo change from baseline in HbA1c for pio+met background only was the fourth step in each hierarchical sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, background antidiabetic medication, renal function at baseline and baseline HbA1c.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing to adjust for multiple comparisons within each dose level, alpha split equally between the doses (2.5%). Empa vs placebo change from baseline in HbA1c for pio+met background only was the fourth step in each hierarchical sequence.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, background antidiabetic medication, renal function at baseline and baseline HbA1c.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hypoglycaemic Events</title>
        <description>Number of patients with hypoglycaemic events, as reported as adverse events.</description>
        <time_frame>From first drug administration until 7 days after last intake of study drug, up to 256 days</time_frame>
        <population>Treated set which included all patients treated with at least one dose of randomised study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycaemic Events</title>
          <description>Number of patients with hypoglycaemic events, as reported as adverse events.</description>
          <population>Treated set which included all patients treated with at least one dose of randomised study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of randomised study medication until 7 days after the last dose, up to 256 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

